193 related articles for article (PubMed ID: 37233759)
21. The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes.
Bi Y; Tong GY; Yang HJ; Cai MY; Ma JH; Liang J; Xin B; Miao H; Peng ZH; Zhu DL
Diabetes Metab Res Rev; 2013 Nov; 29(8):664-72. PubMed ID: 23955995
[TBL] [Abstract][Full Text] [Related]
22. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.
Yarmolinsky J; Bouras E; Constantinescu A; Burrows K; Bull CJ; Vincent EE; Martin RM; Dimopoulou O; Lewis SJ; Moreno V; Vujkovic M; Chang KM; Voight BF; Tsao PS; Gunter MJ; Hampe J; Pellatt AJ; Pharoah PDP; Schoen RE; Gallinger S; Jenkins MA; Pai RK; ; ; Gill D; Tsilidis KK
Diabetologia; 2023 Aug; 66(8):1481-1500. PubMed ID: 37171501
[TBL] [Abstract][Full Text] [Related]
23. Association of GLP1R Polymorphisms With the Incretin Response.
Dorsey-Trevino EG; Kaur V; Mercader JM; Florez JC; Leong A
J Clin Endocrinol Metab; 2022 Aug; 107(9):2580-2588. PubMed ID: 35723666
[TBL] [Abstract][Full Text] [Related]
24. A Genome-Wide Association Study Identifies Blood Disorder-Related Variants Influencing Hemoglobin A
Moon JY; Louie TL; Jain D; Sofer T; Schurmann C; Below JE; Lai CQ; Aviles-Santa ML; Talavera GA; Smith CE; Petty LE; Bottinger EP; Chen YI; Taylor KD; Daviglus ML; Cai J; Wang T; Tucker KL; Ordovás JM; Hanis CL; Loos RJF; Schneiderman N; Rotter JI; Kaplan RC; Qi Q
Diabetes Care; 2019 Sep; 42(9):1784-1791. PubMed ID: 31213470
[TBL] [Abstract][Full Text] [Related]
25. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
Del Prato S; Nauck M; Durán-Garcia S; Maffei L; Rohwedder K; Theuerkauf A; Parikh S
Diabetes Obes Metab; 2015 Jun; 17(6):581-590. PubMed ID: 25735400
[TBL] [Abstract][Full Text] [Related]
26. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
[TBL] [Abstract][Full Text] [Related]
27. A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas.
Li JH; Szczerbinski L; Dawed AY; Kaur V; Todd JN; Pearson ER; Florez JC
Diabetes; 2021 Jan; 70(1):293-300. PubMed ID: 33106254
[TBL] [Abstract][Full Text] [Related]
28. Clinical Review: Safety and Efficacy Comparison between Sulfonylureas and Dipeptidyl Peptidase-4 Inhibitors as Second-Line Therapies in Type 2 Diabetes Mellitus.
Gillani SW; Moosvi AF
Curr Pharm Des; 2020; 26(34):4315-4322. PubMed ID: 32268860
[TBL] [Abstract][Full Text] [Related]
29. Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1-year multicentre study.
Madsbad S; Kilhovd B; Lager I; Mustajoki P; Dejgaard A;
Diabet Med; 2001 May; 18(5):395-401. PubMed ID: 11472451
[TBL] [Abstract][Full Text] [Related]
30. Identification of Genetic Variation Influencing Metformin Response in a Multiancestry Genome-Wide Association Study in the Diabetes Prevention Program (DPP).
Li JH; Perry JA; Jablonski KA; Srinivasan S; Chen L; Todd JN; Harden M; Mercader JM; Pan Q; Dawed AY; Yee SW; Pearson ER; Giacomini KM; Giri A; Hung AM; Xiao S; Williams LK; Franks PW; Hanson RL; Kahn SE; Knowler WC; Pollin TI; Florez JC;
Diabetes; 2023 Aug; 72(8):1161-1172. PubMed ID: 36525397
[TBL] [Abstract][Full Text] [Related]
31. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2017 May; 5(5):CD012204. PubMed ID: 28489279
[TBL] [Abstract][Full Text] [Related]
32. Results of a placebo-controlled study of the metabolic effects of the addition of metformin to sulfonylurea-treated patients. Evidence for a central role of adipose tissue.
Abbasi F; Kamath V; Rizvi AA; Carantoni M; Chen YD; Reaven GM
Diabetes Care; 1997 Dec; 20(12):1863-9. PubMed ID: 9405908
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
34. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus.
Burge MR; Schmitz-Fiorentino K; Fischette C; Qualls CR; Schade DS
JAMA; 1998 Jan; 279(2):137-43. PubMed ID: 9440664
[TBL] [Abstract][Full Text] [Related]
35. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM.
Jeppesen J; Zhou MY; Chen YD; Reaven GM
Diabetes Care; 1994 Oct; 17(10):1093-9. PubMed ID: 7821127
[TBL] [Abstract][Full Text] [Related]
36. Sodium-glucose co-transporter-2 inhibitors, the latest residents on the block: Impact on glycaemic control at a general practice level in England.
Heald AH; Fryer AA; Anderson SG; Livingston M; Lunt M; Davies M; Moreno GYC; Gadsby R; Young RJ; Stedman M
Diabetes Obes Metab; 2018 Jul; 20(7):1659-1669. PubMed ID: 29516618
[TBL] [Abstract][Full Text] [Related]
37. Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.
Zhou K; Yee SW; Seiser EL; van Leeuwen N; Tavendale R; Bennett AJ; Groves CJ; Coleman RL; van der Heijden AA; Beulens JW; de Keyser CE; Zaharenko L; Rotroff DM; Out M; Jablonski KA; Chen L; Javorský M; Židzik J; Levin AM; Williams LK; Dujic T; Semiz S; Kubo M; Chien HC; Maeda S; Witte JS; Wu L; Tkáč I; Kooy A; van Schaik RHN; Stehouwer CDA; Logie L; ; ; ; Sutherland C; Klovins J; Pirags V; Hofman A; Stricker BH; Motsinger-Reif AA; Wagner MJ; Innocenti F; 't Hart LM; Holman RR; McCarthy MI; Hedderson MM; Palmer CNA; Florez JC; Giacomini KM; Pearson ER
Nat Genet; 2016 Sep; 48(9):1055-1059. PubMed ID: 27500523
[TBL] [Abstract][Full Text] [Related]
38. Metagenomic analysis reveals crosstalk between gut microbiota and glucose-lowering drugs targeting the gastrointestinal tract in Chinese patients with type 2 diabetes: a 6 month, two-arm randomised trial.
Zhang X; Ren H; Zhao C; Shi Z; Qiu L; Yang F; Zhou X; Han X; Wu K; Zhong H; Li Y; Li J; Ji L
Diabetologia; 2022 Oct; 65(10):1613-1626. PubMed ID: 35930018
[TBL] [Abstract][Full Text] [Related]
39. Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis.
Wheeler E; Leong A; Liu CT; Hivert MF; Strawbridge RJ; Podmore C; Li M; Yao J; Sim X; Hong J; Chu AY; Zhang W; Wang X; Chen P; Maruthur NM; Porneala BC; Sharp SJ; Jia Y; Kabagambe EK; Chang LC; Chen WM; Elks CE; Evans DS; Fan Q; Giulianini F; Go MJ; Hottenga JJ; Hu Y; Jackson AU; Kanoni S; Kim YJ; Kleber ME; Ladenvall C; Lecoeur C; Lim SH; Lu Y; Mahajan A; Marzi C; Nalls MA; Navarro P; Nolte IM; Rose LM; Rybin DV; Sanna S; Shi Y; Stram DO; Takeuchi F; Tan SP; van der Most PJ; Van Vliet-Ostaptchouk JV; Wong A; Yengo L; Zhao W; Goel A; Martinez Larrad MT; Radke D; Salo P; Tanaka T; van Iperen EPA; Abecasis G; Afaq S; Alizadeh BZ; Bertoni AG; Bonnefond A; Böttcher Y; Bottinger EP; Campbell H; Carlson OD; Chen CH; Cho YS; Garvey WT; Gieger C; Goodarzi MO; Grallert H; Hamsten A; Hartman CA; Herder C; Hsiung CA; Huang J; Igase M; Isono M; Katsuya T; Khor CC; Kiess W; Kohara K; Kovacs P; Lee J; Lee WJ; Lehne B; Li H; Liu J; Lobbens S; Luan J; Lyssenko V; Meitinger T; Miki T; Miljkovic I; Moon S; Mulas A; Müller G; Müller-Nurasyid M; Nagaraja R; Nauck M; Pankow JS; Polasek O; Prokopenko I; Ramos PS; Rasmussen-Torvik L; Rathmann W; Rich SS; Robertson NR; Roden M; Roussel R; Rudan I; Scott RA; Scott WR; Sennblad B; Siscovick DS; Strauch K; Sun L; Swertz M; Tajuddin SM; Taylor KD; Teo YY; Tham YC; Tönjes A; Wareham NJ; Willemsen G; Wilsgaard T; Hingorani AD; ; ; ; Egan J; Ferrucci L; Hovingh GK; Jula A; Kivimaki M; Kumari M; Njølstad I; Palmer CNA; Serrano Ríos M; Stumvoll M; Watkins H; Aung T; Blüher M; Boehnke M; Boomsma DI; Bornstein SR; Chambers JC; Chasman DI; Chen YI; Chen YT; Cheng CY; Cucca F; de Geus EJC; Deloukas P; Evans MK; Fornage M; Friedlander Y; Froguel P; Groop L; Gross MD; Harris TB; Hayward C; Heng CK; Ingelsson E; Kato N; Kim BJ; Koh WP; Kooner JS; Körner A; Kuh D; Kuusisto J; Laakso M; Lin X; Liu Y; Loos RJF; Magnusson PKE; März W; McCarthy MI; Oldehinkel AJ; Ong KK; Pedersen NL; Pereira MA; Peters A; Ridker PM; Sabanayagam C; Sale M; Saleheen D; Saltevo J; Schwarz PE; Sheu WHH; Snieder H; Spector TD; Tabara Y; Tuomilehto J; van Dam RM; Wilson JG; Wilson JF; Wolffenbuttel BHR; Wong TY; Wu JY; Yuan JM; Zonderman AB; Soranzo N; Guo X; Roberts DJ; Florez JC; Sladek R; Dupuis J; Morris AP; Tai ES; Selvin E; Rotter JI; Langenberg C; Barroso I; Meigs JB
PLoS Med; 2017 Sep; 14(9):e1002383. PubMed ID: 28898252
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials.
Dawed AY; Mari A; Brown A; McDonald TJ; Li L; Wang S; Hong MG; Sharma S; Robertson NR; Mahajan A; Wang X; Walker M; Gough S; Hart LM'; Zhou K; Forgie I; Ruetten H; Pavo I; Bhatnagar P; Jones AG; Pearson ER;
Lancet Diabetes Endocrinol; 2023 Jan; 11(1):33-41. PubMed ID: 36528349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
